Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Glucagon-like
100%
Vascular Protective Effect
100%
Diabetes Medications
100%
Cardiovascular Events
28%
Cardiovascular Risk Factors
28%
Cardiovascular Disease
14%
Drug Class
14%
Clinical Trials
14%
Non-diabetic
14%
Weight Loss
14%
High Risk
14%
Hyperglycemia
14%
Risk for Cardiovascular Diseases
14%
Vascular Disease
14%
Risk Factors for Cardiovascular Diseases
14%
Vascular Function
14%
Hypoglycemia
14%
Glycemic Control
14%
Endothelial Function
14%
Beneficial Effects
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Chronic Effects
14%
Lipoprotein Profile
14%
Glucose Control
14%
Loss of Control
14%
Pharmacologic
14%
Blood Pressure Control
14%
Intensive Glycemic Control
14%
Recent Patents
14%
Macrovascular Disease
14%
Intensive Glucose Control
14%
Longitudinal Clinical Trial
14%
Incretin System
14%
Major Cardiovascular Diseases
14%
Patients with Diabetes
14%
Vasculoprotective
14%
Medicine and Dentistry
Diabetes
100%
Glucagon Like Peptide 1
100%
Cardiovascular Disease
71%
Glucose
57%
Clinical Trial
28%
Glycemic Control
28%
Hyperglycemia
14%
Lipoprotein
14%
Blood Pressure
14%
Cardiovascular Disease Risk Factor
14%
Vascular Disease
14%
Endothelial Function
14%
Diabetes Mellitus
14%
Maturity Onset Diabetes of the Young
14%
Hypoglycemia
14%
Patient with Diabetes
14%
Type 2 Diabetes
14%
Pressure Control
14%
Macrovascular Disease
14%
Incretin
14%
Neuroscience
Glucagon-Like Peptide-1
100%
Cardiovascular System
85%
Glucose
57%
Risk Factor
28%
Vascular Disease
14%
Diabetes Mellitus
14%
Hypoglycemia
14%
Hyperglycemia
14%
Incretin
14%